Related Experiment Video
Updated: Mar 19, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation Management in Patients with Pacemaker-Detected Atrial Fibrillation
Lidija Poposka1, Vladimir Boskov1, Dejan Risteski1
1University Clinic of Cardiology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
Insights
For pacemaker patients with asymptomatic atrial fibrillation (AF), episode duration can guide oral anticoagulation therapy decisions. A 1% threshold within 24 hours may indicate when to start anticoagulation if the CHA2DS2-VASc score is 1 or higher.
Area of Science:
- Cardiology
- Medical Device Technology
Background:
- Asymptomatic atrial fibrillation (AF) in pacemaker patients increases thrombo-embolic risk.
- Current guidelines lack consensus on AF episode duration thresholds for initiating oral anticoagulation therapy (OAC).
Purpose of the Study:
- To investigate the correlation between AF episode duration and the need for OAC in pacemaker patients.
- To establish a potential threshold for OAC initiation based on AF burden.
Main Methods:
- A cohort of 104 patients with pacemakers and no prior AF history were monitored for 18 months.
- AF episodes were recorded, and OAC was initiated based on AF occurrence and CHA2DS2-VASc score (≥1).
Main Results:
- 33 patients developed AF during follow-up; 17 initiated OAC.
- OAC initiation showed a significant correlation with AF episode duration (r=0.502, p=0.003).
- No thrombo-embolic complications occurred in any patient during the study period.
Conclusions:
- An AF episode burden exceeding 1% within 24 hours may serve as an indicator for OAC initiation in pacemaker patients with a CHA2DS2-VASc score ≥1.
- This threshold could aid clinical decision-making for anticoagulation in this patient group, given the absence of thrombo-embolic events in the study.
Introduction:
In patients with an implanted pacemaker, asymptomatic atrial fibrillation (AF) is associated with an increased risk of thrombo-embolic complications. There is still no consensus which duration of episodes of atrial fibrillation should be taken as an indicator for inclusion of oral anticoagulation therapy (OAC).
Material And Methods:
A total of 104 patients who had no AF episodes in the past and have an indication for permanent pacing were included in the study.
Results:
During an average follow-up of 18 months, 33 of the patients developed episodes of AF. Inclusion of OAC was performed in 17 patients, in whom AF was recorded, although in all patients CHA2DS2-VASc score was ≥ 1. The inclusion of OAC showed a statistically significant correlation with increasing duration of episodes of AF (r = 0.502, p = 0.003). During the follow-up period none of the patients developed thrombo-embolic complication.
Conclusion:
Considering that our group of patients had no thrombo-embolic events, we could conclude that dividing the AF episodes in less than 1% in 24 hours and longer than 1% within 24 hours could be an indicator for decision-making to include OAK if the CHA2DS2-VASc score is ≥ 1.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
01:29Venous Thrombosis III: Interprofessional Care
01:26Mitral Stenosis III: Medical Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:25Aortic Regurgitation III: Medical Management
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias